EUCTR2005-000200-14-GB
Active, not recruiting
Phase 1
A randomised, double-blinded comparison of the effectiveness of intravenously administered Ketoralac versus Dexamethasone in the treatment of pain following surgical removal of third molar teeth under intravenous sedation and local anaesthesia – a pilot study. - North Bristol Oral surgery Intravenous Sedation Study
orth Bristol NHS Trust0 sites30 target enrollmentApril 21, 2005
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- orth Bristol NHS Trust
- Enrollment
- 30
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who require the surgical removal of impacted third molars under intravenous sedation and local anaesthesia. These patients will generally be young, fit and healthy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Patients who are known to have an intolerance of non\-steroidal anti\-inflammatory painkillers, or who have asthma that can be precipitated by the use of non\-steroidal anti\-inflammatory painkillers.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A randomised, double-blind study comparing the efficacy and safety of 145mg NanoCrystal® fenofibrate, 10mg ezetimibe and their combination in patients with type IIb dyslipidemia and features of the metabolic syndrome. - see protocol page 1Patients with type IIb dyslipidemia and features of the metabolic syndrome.EUCTR2004-002408-13-DEFOURNIER Laboratories Ireland Ltd186
Active, not recruiting
Not Applicable
A randomised, double-blind study comparing the efficacy and safety of 145mg NanoCrystal® fenofibrate, 10mg ezetimibe and their combination in patients with type IIb dyslipidemia and features of the metabolic syndrome. - see protocol page 1Patients with type IIb dyslipidemia and features of the metabolic syndrome.EUCTR2004-002408-13-BEFOURNIER Laboratories Ireland Ltd186
Completed
Phase 4
Comparing the effectiveness of testosterone-blocking medications in trans and gender diverse individualstransgenderbody compositionbreast growthMetabolic and Endocrine - Other endocrine disordersACTRN12620000339954Austin Health66
Active, not recruiting
Not Applicable
A randomized, double-blind study comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs metformin alone in patients with type 2 diabetes mellitus and dyslipidemia not appropriately controlled with a statin - fenofibrate and metformin fixed combination vs metformiPatients with type 2 diabetes mellitus and dyslipidemia not appropriately controlled with a statinEUCTR2006-000924-15-HUFOURNIER Laboratories Ireland Ltd480
Active, not recruiting
Phase 1
Efficacy and safety of trazodone OAD and venlafaxine XR in the treatment of Major Depressive Disorder.Major depressive disorderMedDRA version: 19.0Level: SOCClassification code 10037175Term: Psychiatric disordersSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 19.0Level: HLGTClassification code 10012375Term: Depressed mood disorders and disturbancesSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 19.0Level: HLTClassification code 10012401Term: Depressive disordersSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2011-005878-37-ESAziende Chimiche Riunite Angelini Francesco - ACRAF S.p.A.360